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Abstract
Background
Fibrinogen is an essential hemostatic factor and cardiovascular disease risk factor. Early
attempts at evaluating the causal effect of fibrinogen on coronary heart disease (CHD) and
myocardial infraction (MI) using Mendelian randomization (MR) used single variant
approaches, and did not take advantage of recent genome-wide association studies
(GWAS) or multi-variant, pleiotropy robust MR methodologies.
Methods and findings
We evaluated evidence for a causal effect of fibrinogen on both CHD and MI using MR. We
used both an allele score approach and pleiotropy robust MR models. The allele score was
composed of 38 fibrinogen-associated variants from recent GWAS. Initial analyses using
the allele score used a meta-analysis of 11 European-ancestry prospective cohorts, free of
CHD and MI at baseline, to examine incidence CHD and MI. We also applied 2 sample MR
methods with data from a prevalent CHD and MI GWAS. Results are given in terms of the
hazard ratio (HR) or odds ratio (OR), depending on the study design, and associated 95%
confidence interval (CI).
In single variant analyses no causal effect of fibrinogen on CHD or MI was observed. In
multi-variant analyses using incidence CHD cases and the allele score approach, the esti-
mated causal effect (HR) of a 1 g/L higher fibrinogen concentration was 1.62 (CI = 1.12,
2.36) when using incident cases and the allele score approach. In 2 sample MR analyses
that accounted for pleiotropy, the causal estimate (OR) was reduced to 1.18 (CI = 0.98,
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1.42) and 1.09 (CI = 0.89, 1.33) in the 2 most precise (smallest CI) models, out of 4 models
evaluated. In the 2 sample MR analyses for MI, there was only very weak evidence of a
causal effect in only 1 out of 4 models.
Conclusions
A small causal effect of fibrinogen on CHD is observed using multi-variant MR approaches
which account for pleiotropy, but not single variant MR approaches. Taken together, results
indicate that even with large sample sizes and multi-variant approaches MR analyses still
cannot exclude the null when estimating the causal effect of fibrinogen on CHD, but that any
potential causal effect is likely to be much smaller than observed in epidemiological studies.
Introduction
Fibrinogen is an essential component of the clotting and hemostasis system with a strong
genetic basis [1–3]. Although it primarily serves as the precursor to fibrin, it also carries out
several other functions, including enhancing platelet aggregation and mediating inflammation
[4, 5]. In epidemiologic studies, fibrinogen levels are associated with coronary heart disease
(CHD) [6–8], myocardial infarction (MI) [9, 10], ischemic stroke [11, 12], and abdominal aor-
tic aneurysm [13, 14].
Mendelian randomization (MR) is an instrumental variable analysis method which uses
genetic variants as instruments to uncover evidence for a causal relationship between a modifi-
able risk factor and outcome.[15] MR studies utilizing a limited number of genetic variants in
the FGB promoter have yielded little evidence of a causal effect of fibrinogen on CHD or MI
[16–18]. In a genome-wide association study (GWAS) for fibrinogen, each fibrinogen-associ-
ated variant was individually evaluated for association with CHD, but no associations provided
substantial evidence of a causal effect [19]. To date MR studies of fibrinogen have been limited
to single variant approaches which have not taken into account recent GWAS findings or
modern, multi-variant MR methodologies. Here we re-examine the potential for fibrinogen to
be a causal biomarker for CHD and MI, taking into account these improved approaches.
Results
For incident CHD there were 3,147 incident events observed in 15,427 participants in the dis-
covery analyses, and 1,482 incident events among the 34,209 participants in the replication
analyses. Of the 18,798 participants in the incident MI discovery analyses, 1,711 had an inci-
dent MI. For the replication analyses, there were 687 incident MI events out of the 33,288 par-
ticipants. Table 1 contains the distributions of clinical covariates and fibrinogen. The FGB
variant rs1800790 (commonly used in previous fibrinogen MR analyses) had a weaker associa-
tion (by effect size) than the allele score (Table A in S1 File). In single variant analyses of
rs1800790 the estimated causal effect appeared to be centered around the null with little evi-
dence of a causal effect of fibrinogen on CHD or MI (Table B in S1 File), consistent with pub-
lished literature. In multi-variant MR using the 2SC model, we observed evidence of a causal
association of fibrinogen on incident CHD in the discovery and replication analyses which
remained in a combined analysis of all cohorts (HR = 1.75; CI = 1.22–2.51; P = 0.002; Fig 1).
For incident MI, we observed an elevated HR that included the null, even in the combined
analysis (HR = 1.45; CI = 0.85–2.49; P = 0.17; Fig 2).
Mendelian randomization study of fibrinogen and coronary heart disease
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Pleiotropy robust models
In sensitivity analyses four MR methods were used each of which is at least partially robust to
horizontal pleiotropy under differing assumptions. Sensitivity analyses were performed using
summary statistics from the CARDIoGRAMplusC4D consortium [34] which used prevalent
cases, but had a larger sample size than the CHARGE cohorts (60,801 prevalent cases and
123,504 controls). For CHD, three of the four models showed a positive effect, albeit smaller
than the effect observed in the 2SC model, with the MR PRESSO method having the largest
causal OR (OR = 1.18; CI = 0.98, 1.42; Table 2). For MI only the MR PRESSO method showed
a causal OR> 1 (OR = 1.16; CI = 0.98, 1.38; Table 2), again substantially reduced from that
Table 1. Clinical covariates.
Discovery Replication
KORA GENOA ARIC CHS GeneSTAR FHS RS MESA WGHS LURIC SHIP
N 3,788 417 8,815 2,939 594 1,828 834 2,506 27,553 921 3,229
Mean ± SD†
MI follow-up time
(y)
8.44 ± 1.5 - 20.8 ± 6.0 10.3 ± 6.0 6.72 ± 3.6 17.9 ± 5.3 9.32 ± 3.2 6.25 ± 1.1 17.5 ± 3.8 - 11.1 ± 0.8��
CHD follow-up
time (y)
- 10.4 ± 3.6 20.0 ± 6.5 10.3 ± 5.9 6.07 ± 3.2 17.9 ± 5.3 9.18 ± 3.2 6.18 ± 1.2 17.4 ± 4.0 9.43 ± 2.6 11.1 ± 0.8��
Age (y) 49.2 ± 13.9 58.6 ± 10.0 54.2 ± 5.68 72.4 ± 5.4 51.1 ± 11.3 53.8 ± 10.0 72.2 ± 6.8 62.7 ± 10.2 54.6 ± 7.1 60.1 ± 11.5 46.4 ± 15.1
BMI (kg/m2) 27.2 ± 4.7 30.6 ± 6.3 27.0 ± 4.9 26.2 ± 4.4 29.3 ± 6.3 27.4 ± 4.93 26.7 ± 3.8 27.7 ± 5.1 25.1 ± 6.8 27.5 ± 4.4 27.0 ± 4.8
Fibrinogen (g/L) 2.60 ± 0.6 3.19 ± 0.8 2.95 ± 0.61 3.14 ± 0.61 3.83 ± 1.1 3.14 ± 0.61 3.95 ± 0.87 3.35 ± 0.70 3.59 ± 0.78 3.69 ± 0.90 2.95 ± 0.68
log(Fibrinogen) 0.94 ± 0.22 1.11 ± 0.36 3.97 ± 0.11 1.13 ± 0.19 1.30 ± 0.27 1.12 ± 0.19 1.35 ± 0.21 1.19 ± 0.20 1.25 ± 0.22 1.28 ± 0.26 1.06 ± 0.22
HDL (mg/dL) 57.9 ± 17.0 52.5 ± 14.3 51.1 ± 16.7 55.8 ± 15.9 52.1 ± 15.8 51.3 ± 15.3 204 ± 24.5 52.4 ± 15.7 53.1 ± 16.6 41.8 ± 11.7 57.0 ± 17.1
LDL (mg/dL) 137 ± 41.4 117 ± 31.0 137 ± 37.6 134 ± 35.8 130 ± 41.6 126 ± 33.0 104 ± 12.5 117 ± 30.3 122 ± 37.3 121 ± 33.7 137.3 ± 44.2
N (%)
MI 109 (2.88) - 859 (9.74) 498 (16.9) 30 (5.05) 158 (8.64) 57 (6.83) 62 (2.50) 413 (1.50) - 212 (6.5)
CHD - 77 (18.5) 1,625
(18.4)
942 (32.1) 85 (14.31) 305 (16.7) 113 (13.6) 128 (5.10) 1,035 (3.76) 59 (6.41) 260 (8.0)
Sex (male) 1,854
(48.9)
156 (37.4) 3,983
(45.2)
1,792
(61.0)
321 (54.0) 829 (45.0) 421 (50.5) 1,308
(52.2)
0 (0.00) 499 (54.2) 1,537 (47.6)
Current Smokers 962 (25.4) 47 (11.3) 2,633
(29.9)
322 (11.0) 135 (22.8) 341 (18.7) 144 (17.3) 286 (11.4) 3200 (11.6) 197 (21.4) 1,096 (33.9)
Former Smokers 1,262
(33.3)
157 (37.6) 2,050
(23.3)
1,216
(41.4)
202 (34.0) 404� 429 (51.4) 1,109
(44.4)
10,096
(36.6)
273 (29.6) 1,004 (31.1)
Never Smokers 1,560
(41.2)
213 (51.0) 4,109
(46.6)
1401 (47.7) 257 (43.3) 911� 261 (31.3) 1,104
(44.2)
14,233
(51.7)
451 (49.0) 1,129 (35.0)
Hypertension 1,079
(28.5)
310 (74.3) 2,272
(25.8)
1549 (52.7) 261 (43.94) 563 (30.8) 204 (24.5) 1,097
(43.8)
6,654 (24.2) 625 (67.5) 671 (20.8)
Type 2 Diabetes 565 (14.9) 52 (12.5) 1,659
(18.8)
349 (11.9) 59 (9.93) 129 (7.10) 104 (12.5) 150 (6.70) 0 (0.00) 283 (30.7) 174 (5.4)
Clinical covariates for all participating cohorts. KORA did not have incident CHD data and thus did not participate in these analyses. GENOA and LURIC had too few
incident MI cases for analysis. ANOVA and Chi-squared tests showed significant differences across cohorts for all clinical covariates with P < 0.001 for all tests.
BMI = body mass index; CHD = coronary heart disease; HDL = high-density lipoprotein cholesterol; LDL = low-density lipoprotein cholesterol; MI = myocardial
infarction; NA = not available
� For FHS 172 individuals were not current smokers but were not distinguished as former vs never smokers thus percentages were not computed for these categories
and the N for those with information is given.
�� For SHIP only interval censored data was available. Follow-up time represents the time from initial exam to final exam.
† Continuous variables are summarized as the mean ± standard deviation while binary variables are summarized as the sample size "N" and percentage of samples for a
given level of the variable
https://doi.org/10.1371/journal.pone.0216222.t001
Mendelian randomization study of fibrinogen and coronary heart disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0216222 May 10, 2019 4 / 18
observed in the 2SC model. All other models for MI showed little evidence of a causal effect of
fibrinogen on MI.
We also examined MR associations of fibrinogen on metabolic CHD risk factors using pub-
lished data available in MR-base as described in the methods. While fibrinogen showed a posi-
tive causal effect estimate for some of the CHD risk factors, none provided substantial
evidence for excluding the null after accounting for the number of tests performed (Table C S1
File).
Discussion
The attractiveness of fibrinogen as a causal factor in CHD comes from its roles in both throm-
bosis and inflammation. Fibrinogen is the precursor to fibrin, which interlinks into a mesh
that acts as the scaffold of blood clots. Additionally, fibrinogen also has an active role in platelet
aggregation,[20] thus contributing to the formation of platelet plugs. By binding the CD11b/
CD18 integrin receptor fibrinogen activates the NF-κB pathway [5], an important pathway in
inflammation as well as the formation, destabilization, and rupture of atherosclerotic plaques
[21, 22]. As a modifiable risk factor [23] even a small causal effect of fibrinogen on CHD could
have substantial public health implications.
Using the allele score approach, a 1 g/L higher fibrinogen concentration was causally associ-
ated with a HR of 1.75 (CI = 1.22–2.51) in the combined cohort analysis for CHD. However,
Fig 1. CHD Forest plot. Forest plot of the CHD MR analysis for the discovery, replication, and combined sets of
cohorts. Shown beside each cohort name is the sample size and number of incident CHD events given as (N events; N
total). CHD = coronary heart disease; FE = fixed-effects; HR = hazard ratio; CI = confidence interval.
https://doi.org/10.1371/journal.pone.0216222.g001
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sensitivity analysis using methods robust to pleiotropy arising from independent effects of
SNPs on exposure and outcome (which could invalidate MR analyses) suggested a substan-
tially weaker causal effect on CHD even for the model with the strongest effect estimate
Fig 2. MI Forest plot. Forest plot of the MI MR analysis for the discovery, replication, and combined sets of cohorts.
Shown beside each cohort name is the sample size and number of incident MI events given as (N events; N total).
MI = myocardial infarction, FE = fixed-effects, HR = hazard ratio, CI = confidence interval.
https://doi.org/10.1371/journal.pone.0216222.g002
Table 2. Multi-variant, pleiotropy robust MR methods.
Method Robust to pleiotropy by . . . CHD Causal OR
(95% CI)
MI Causal OR
(95% CI)
MR Egger Intercept-based adjustment for global effect of
pleiotropy
0.98 (0.70, 1.39) 0.89 (0.63, 1.26)
Weighted MBE
(phi = 1)
Assuming causal effect is most common shared
effect across variants
1.09 (0.89, 1.33) 0.98 (0.79, 1.21)
Weighted Median Assuming most (� 50%) genetic instruments are
unaffected by pleiotropy
1.12 (0.91, 1.37) 1.03 (0.82, 1.29)
MR PRESSO Assuming <50% of genetic instruments have
horizontal pleiotropy
1.18 (0.98, 1.42) 1.17 (0.98, 1.40)
To further examine potential effects of pleiotropy we ran several multi-variant, pleiotropy robust models including
MR Egger, Weighted Mode Based Estimator (MBE), Weighted Median, and MR PRESSO. Each uses a different
means to account for pleiotropy and has different assumptions used to estimate the causal effect in the presence of
pleiotropy. Odds ratios are per 1 g/L increase in genetically determined fibrinogen. CHD = coronary heart disease;
CI = confidence interval; MI = myocardial infarction; MR = mendelian randomization
https://doi.org/10.1371/journal.pone.0216222.t002
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(OR = 1.18 per 1 g/L higher fibrinogen; CI = 0.98, 1.42), and the MR Egger model showed vir-
tually no evidence of a causal effect–though the wide 95% confidence interval encompassed
effects from all other models. Overall, when accounting for potential horizontal pleiotropy, the
accumulated evidence points to a substantially weaker casual effect of fibrinogen on CHD than
the observational risk ratio of 1.8 (CI = 1.6, 2.0) previously reported [6]. Using rs1800790 in a
single variant MR analysis, there was limited evidence of any causal effect, though the 95%
confidence interval could not exclude positive estimated causal effects seen in multi-variant
analyses. In combination these analyses suggest that after accounting for horizontal pleiotropy
the effect of fibrinogen on CHD is likely to be small, if any at all, and that current MR estimates
of the potential causal effect remain unable to exclude the null, despite large sample sizes and
the latest methodologies. Discrepancies in the estimates of the causal effect of fibrinogen on
CHD obtained by different MR approaches are likely to be due to differences in their approach
to accounting for horizontal pleiotropy, given the clear influence of such pleiotropy on esti-
mates from observations studies.
Comparison with previous MR analyses
Previous MR studies assessing the causal effect of fibrinogen on CHD or MI focused exclu-
sively on rs1800790 [24, 25]. In a few studies one additional variant also in the FGB promoter
region was examined, however this variant is in nearly complete LD with rs1800790, particu-
larly in Europeans [16, 18]. The allele score was a better predictor of fibrinogen than
rs1800790 alone (Table A in S1 File). Though the allele score estimated a causal effect of fibrin-
ogen on CHD similar to observational studies, much of this appeared to be driven by pleiot-
ropy as estimated effects decreased in models more robust to pleiotropy (Table 2). This
highlights the need to balance increased power from multi-variant approaches with the poten-
tial for increased pleiotropy in these instruments.
For the CHARGE cohorts we used exclusively incident cases whereas previous studies utilized
populations composed entirely or primarily of prevalent cases. In some instances, the use of prev-
alent cases may bias MR studies such as if the disease subsequently what is perceived as a disease
risk factor, e.g. if CHD leads to higher fibrinogen as opposed to the reverse, then reverse con-
founding can still occur even in an MR setting [26]. Additionally, if the risk factor were to affect
severity of an event, e.g. the fatality of MI, then use of prevalent cases may dilute the MR-esti-
mated causal effect as the most severe cases may not be observed due to being too ill to participate
or suffering a fatal event. This type of prevalence-incidence bias is not exclusive to MR analyses
[27–29]. However, care must still be taken when interpreting results from incident case MR stud-
ies as the exclusion of prevalent cases is equivalent to conditioning on disease status at baseline.
This has the potential to introduce bias in the form of an exclusion restriction violation.[30]
Whether bias is introduced and the degree of confounding are dependent on the actual biological
processes that account for the relationship between the genetic instrument(s) chosen, the modifi-
able risk factor, and outcome in the MR analysis. When performing incident case MR it is best to
combine the efforts with MR analyses including prevalent cases and interpret results for both
with careful consideration towards their underlying assumptions, strengths, and weaknesses.
In general, our results are compatible with previous MR studies, however we use more
modern methods, including multi-variant, pleiotropy robust methods, able to produce smaller
confidence intervals and which indicate that after accounting for pleiotropy there may be a
small positive effect of fibrinogen on CHD. This is particularly true for the methods producing
the most precise estimates. However, these results warrant further investigations as confidence
intervals for some models were still wide and with results for the single variant and MR Egger
analyses possibly more consistent with no causal effect than even a small causal effect.
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Strengths and limitations
As with all MR studies the causal effects estimated here are based on regression estimates for
genetic variants and are only valid, causal estimates under the assumptions of MR. Addition-
ally, causal estimates generated via MR methodologies are for lifelong, genetically determined
increases in the exposure, e.g. fibrinogen, which means that caution should be exercised when
applying clinical interpretations or attempting to translate results into estimates of an interven-
tion [31, 32]. In the initial analysis a meta-analysis was performed across studies which were
heterogeneous in their distribution of underlying clinical covariates (Table 1). Though there
was heterogeneity in the clinical covariate distribution, the allele score variants were evaluated
for associations with these clinical covariates. Additionally, in the two sample MR we used
approaches robust to confounding from pleiotropy due to associations between SNPs and
other clinical covariates, such as body mass index, which might lie outside any causal pathway
linking fibrinogen and CHD. This study had some overlap between studies involved in the
GWAS used to select fibrinogen variants and those used in the MR analyses. Our approach to
mitigate this was to replicate the allele score analysis in an independent set of cohorts. For the
pleiotropy robust 2-sample MR approaches this overlap was unavoidable, however there was
no overlap for the cases which means that unbiased estimates should be obtained [33]. A
strength of the study is the use of incident cases for the allele score model approach which
reduces the potential for bias from reverse confounding (which can still affect MR studies) and
prevalence-incidence bias. Additionally, even though the allele score approach was sensitive to
horizontal pleiotropy we used an array of additional approaches that were each partially robust
to horizontal pleiotropy through different assumptions about the nature of the pleiotropy.
These models often have lower power than other approaches, which motivated our use of a
previously published GWAS which had 60,801 prevalent cases and 123,504 controls [34].
However, to prevent potential bias and more closely align with our initial analyses, a large sam-
ple size of incident cases independent of those used to evaluate associations between genetic
variants and fibrinogen would have been preferable.
Conclusion
Fibrinogen represents an important role in thrombosis, platelet aggregation, and inflammation
making it a promising risk factor for CHD. Despite the epidemiological evidence, MR studies
using prevalent cases and single variant approaches have consistently shown no causal effect of
fibrinogen on CHD. Out results indicate that epidemiologic studies may substantially over-
estimate any causal effect of fibrinogen on CHD. While some MR models which accounted for
pleiotropy did show a modest causal effect, the 95% confidence intervals still contained the
null indicating that researchers should exercise caution in interpreting these results. Though, it
may be tempting to relate these results to the utility of fibrinogen in clinical testing, caution is
urged in this endeavor. Causal estimates, null or not, are at best imperfect proxies for the
potential utility of a biomarker in a clinical setting, and other estimates, e.g. receiver operating
characteristic, positive/negative predictive value, are important to consider. Our results suggest
any causal effect of fibrinogen on CHD is likely to be small, and resolving any causal effect will
require further analyses using larger sample sizes and more precise methods.
Methods
This study was conducted within the Cohorts for Heart and Aging Research in Genomic Epi-
demiology (CHARGE) consortium [35] using 11 European-ancestry cohorts. For incident
CHD, six cohorts participated in the initial (discovery) analyses (N = 15,427), and four cohorts
(N = 34,209) contributed data for replication. For incident MI, six cohorts participated in the
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discovery (N = 18,798), and three cohorts participated in the replication (N = 33,288) analyses.
Details on all cohorts are given in the Supplemental Materials and the clinical covariates in
Table 1, and Fig 3 outlines all analyses. Data collection analysis for all cohorts was approved by
their respective Institutional Review Boards and/or ethical committees, and all cohorts
obtained written, informed consent from participants.
Assessment of CHD and MI
We defined incident CHD as validated, incident fatal or non-fatal CHD events which included:
validated hospitalized MI, CHD-related hospitalizations, definite CHD deaths, likely CHD
deaths, and CHD-related revascularization procedures, e.g. percutaneous coronary interven-
tion and coronary artery bypass grafting. Incident MI was defined as a validated fatal or non-
fatal MI and included definite MI hospitalizations. For cohorts that used questionnaires as a
component of the follow-up procedures, all events were corroborated with medical records
and/or review by trained medical personnel. Cohort specific details are given in the Supple-
mental Online Methods.
Fibrinogen assessment
Fibrinogen was assessed by multiple methods, with seven cohorts using the Clauss method
[36]. Of the remaining four cohorts, RS used a clotting time-derived method to assess fibrino-
gen concentrations, while KORA, MESA, and WGHS used immunological assays to assess
total fibrinogen. Comparisons of these three methods have shown that the Class and clotting-
time derived methods have very similar means, while the immunological assays can have
slightly lower means [37]. However, the correlations between the methods have been reported
to be high, with Pearson correlations > 0.95 [38]. Previous studies have also found that effect
estimates obtained using the different fibrinogen assessment methods are comparable [1, 39,
40]. We also did not observe heterogeneity in effect estimates by fibrinogen assessment
method.
Fig 3. Study outline. Outline of analyses using the allele score, rs1800790 and 2 Sample MR approaches including the
analytic method used to estimate the causal effect, subject to valid MR assumptions, for all stages of the analysis.
CHD = coronary heart disease; MR = Mendelian Randomization; MI = myocardial infarction.
https://doi.org/10.1371/journal.pone.0216222.g003
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Genotyping and imputation
Genotyping and imputation were performed separately in all cohorts, per published methods
[41]. All participating studies used either the HapMap build 36 [42], 1000 Genomes phase I
version 3, or 1000 Genomes phase I version 2 reference panel for imputation [43]. Imputation
was performed via MACH[44] or IMPUTE [45]. Low quality variants were excluded in line
with previously published approaches: MACH imputation quality < 0.3 or IMPUTE imputa-
tion quality < 0.4 [41].
Creation of the allele score
We evaluated 69 variants associated with fibrinogen in at least one of three recent genome/
exome-wide association studies [2, 19, 41] for inclusion into the allele score [46]. We applied
four criteria to each variant to improve the plausibility that each meets the MR assumptions.
First, to ensure that the variants were not correlated with known risk factors for cardiovascular
disease (CVD), the Spearman correlation between each of the variants and body mass index
(BMI), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol,
type 2 diabetes mellitus (binary), hypertension (binary), and smoking (ever, never, current)
was tested within each cohort and any variants with a Spearman correlation greater than 0.10
in any cohort for any of these outcomes were removed. Second, the variants were tested for
linkage disequilibrium (LD) with known CHD loci [34, 47–56] using SNAP from the Broad
Institute with LD patterns coming from European ancestry individuals [57]. As no variant had
r2 > 0.20 with a CHD locus, they were considered independent of known CHD loci. Next, we
reduced pairs of variants in high LD (r2 > 0.70) by preferentially retaining those variants that
were found in the largest genome-wide scan [41]. Finally, we eliminated any variants that were
missing across any of the discovery cohorts, leaving 38 variants that composed the allele score
(Table D in S1 File). We tested the allele score for association with each of the aforementioned
CHD risk factors in each cohort as well as in a meta-analysis of all cohorts. The allele score was
not associated with any CHD risk factor in the meta-analysis after a Bonferroni correction for
the six tests performed (P> 0.008; Table E in S1 File). Six variants from the allele score which
were unavailable in one or more replication cohorts were removed from the allele score in the
replication phase to ensure a consistent allele score in the replication meta-analysis (Table D
in S1 File). In a sensitivity analysis these variants were also removed from the discovery cohorts
and the causal effect evaluated in a combined meta-analysis.
Each genotype was aligned prior to summing to create the score so that the designated effect
allele corresponded to a positive association with fibrinogen according to the direction of effect
in the largest and most recent fibrinogen GWAS [19].
Mendelian randomization
MR is a powerful framework that uses genetic variants as instrumental variables to infer causal
relationships between a defined exposure and outcome. The causal effect estimated by MR is
the alteration in exposure due to genetic variation and is thus assumed to be over the entire life
course. There are three assumptions for a genetic variant to be a valid instrument for MR [58]
1. The genetic variant is independent of confounders of exposure and outcome under
examination
2. The genetic variant is associated with the exposure
3. The genetic variant is independent of the outcome conditional on the exposure and any
confounders
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In addition to these three conditions, valid estimates from MR are dependent on any
parametric assumptions of the model being used to estimate relevant coefficients and standard
errors.
Our initial MR analyses used a two-stage procedure employing a Cox regression model
(2SC). To improve power, we regressed fibrinogen on age and sex and used the resulting resid-
uals as input to the 2SC analyses. In the first stage of the 2SC procedure the fibrinogen residu-
als were regressed on the allele score. In the second stage the predicted values from the first
stage regression were associated with incident MI or CHD via a Cox proportional hazards
model. This approach is similar to the two-stage predictor-substitution MR approach [59–61],
and results from the 2SC model are given per unit (g/L) increase in the fibrinogen residuals.
We used a fixed effects model for all meta-analyses since we observed little heterogeneity
according to the Q-statistics [62] (P(Q) > 0.05 for all analyses). We also compared associations
with our allele score to those obtained using a single variant, FGB -455G>A (rs1800790),
which is a commonly used variant for fibrinogen MR analyses [16, 18]. We tested the allele
score in the discovery cohorts and replication cohorts separately as well as in a combined
meta-analysis. We separated the discovery and replication cohorts to evaluate any evidence for
bias produced by selecting the variants for the allele score and testing the association of the
allele score with incident CHD and MI both in the discovery cohort. As the replication cohort
was not used to select variants for the allele score it would not suffer from such bias.
We performed sensitivity analyses using four pleiotropy robust methods each of which uses
a different approach to partially relax the no horizontal pleiotropy assumption of MR analyses:
[63] MR-Egger [58], MR mode based estimate (MBE),[64] MR PRESSO [65], and Weighted
median [66]. For these sensitivity analyses, we used the prevalent CHD and MI GWAS results
from CARDIoGRAMplusC4D consortium [34] as it had a larger sample size (60,801 prevalent
cases and 123,504 controls) and these methods often have lower power to detect effects. For
estimates of variant effects on fibrinogen we used fixed-effects meta-analysis estimates from
the 11 cohorts in these analyses. Since an individual cannot be both a prevalent and incident
CHD or MI case at the same sampling, there was no overlap amongst the cases between our
incident analyses and the prevalent cases used in the CARDIoGRAMplusC4D GWAS. There
would still be some overlap amongst the non-cases/controls which could bias estimates
towards the null.
We also examined whether fibrinogen showed evidence for a causal effect on 7 metabolic
CHD risk factors using MR-base (www.mrbase.org), a database of published GWAS available
for MR [67]. We focused on metabolic CHD risk factors as initial results indicated that body
mass index was the trait with which our allele score showed the strongest evidence for pleiot-
ropy—potentially horizontal (i.e. SNPs affecting fibrinogen and CHD via independent path-
ways) and vertical (i.e. fibrinogen-associated SNPs also associated with risk factors
downstream of fibrinogen) as the associations did not distinguish between the two. The CHD
risk factors were body mass index [68], waist circumference [69], waist-to-hip ratio [69], low-
density lipoprotein cholesterol [70], triglycerides [70], homeostatic model assessment insulin
resistance (HOMA-IR) [71], and Type 2 diabetes [72]. As MR-base only contains published
GWAS we used the most recently published GWAS for fibrinogen for our variant-fibrinogen
associations [1] but limited to those variants present in our allele score. For the CHD risk fac-
tors we compared causal effect estimates obtained from the inverse variance weighted method
(which assumes no unbalanced horizontal pleiotropy), to those from the pleiotropy robust MR
Egger, and Weighted median methods. All three methodologies were implemented in MR-
base.
Statistical analyses were performed in R [73]. Meta-analyses were performed using the R
package metaphor [74]. Cox models were estimated via the coxph function in the R package
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survival [75] with the exception of SHIP where the survreg function was used with an exponen-
tial distribution to account for the interval censored data. MR-Egger and weighted median
results were performed using the R package MendelianRandomization and Two Sample MR
[67]. MR MBE analyses were performed using the methods given by Hartwig et al [64]. The
default bandwidth (φ = 1) was used for MR MBE as results did not show sensitivity to the
choice of bandwidth. MR PRESSO analyses were performed using code available at the MR
PRESSO GitHub repository (https://github.com/rondolab/MR-PRESSO) [65]. We used the
robust MR estimates from MR PRESSO which are equivalent to performing an inverse-vari-
ance weighted MR analysis after removing outlying variants, which may be influenced by hori-
zontal pleiotropy, as identified by MR PRESSO. Results from the 2SC model are reported in
terms of the hazard ratio (HR), while all results that utilize the prevalent disease GWAS are
reported in terms of the odds ratio (OR). All HR and OR are given per 1 g/L higher fibrinogen.
All confidence intervals (CI) reported are 95% CI.
Supporting information
S1 File. Supplemental Methods and Tables v2. File containing the Supplemental Online
Methods (including cohort specific information) as well as the Supplemental Tables (A-E).
Table A. Association between allele score (AS) and fibrinogen as well as rs1800790 (FGB
-455G>A) and fibrinogen. Table contains association between AS and fibrinogen as well as
the association between FGB variant rs1800790 with fibrinogen. Also given is the association
between the AS and fibrinogen after rescaling (RS) the AS in each cohort so that a unit of 1
represented 50% of the range. This transformation allows the allele score associations to be
more directly compared with those for rs1800790. Rs1800790 was unavailable in SHIP. The
meta-analysis represents a fixed effects meta-analysis Table B. Comparison of allele score
and rs1800790 as genetic instruments for CHD. Comparison of the allele score vs rs1800790
as a genetic instrument for CHD. 2SC = two-stage Cox (2SC) model; CI = 95% confidence
interval; HR = Hazard Ratio; MR = Mendelian Randomization; OR = Odds Ratio; Q =
Cochran’s Q; SE = standard error. Table C. Estimates of causal effect of fibrinogen on meta-
bolic CHD risk factors. As body mass index was the coronary heart disease (CHD) trait with
the most evidence for pleiotropic effects from our allele score we used 3 Mendelian Randomi-
zation (MR) methods from as implemented in MR-base (www.mrbase.org)[4]. MR-base uses
published genome-wide association studies (GWAS) to perform 2-sample MR. For the genetic
variant-fibrinogen associations we used the most recently published fibrinogen GWAS.[5] Ref-
erences and sample sizes for each of the CHD risk factor outcomes appear in the table. Only
variants that were a part of the allele score were used in the MR analyses, with each GWAS
having between 23 and 32 of the 38 variants represented. HOMA-IR = homeostatic model
assessment insulin resistance; LDL = low-density lipoprotein, OR = odds ratio; SD = standard
deviation; SE = standard error; SNP = single nucleotide polymorphism. Table D. Allele Score
Variants. Variants which composed the allele score along with their availability in each cohort
as well as selection from either the 1000 Genomes imputation GWAS by de Vries et al,[1] the
meta-analysis by Sabater-Lleal et al,[2] or the rare and low-frequency variant meta-analysis by
Huffman et al,[3] and the published direction of association. NA indicates that the variant was
not available. All variants were available for all discovery cohorts by design, thus only the repli-
cation cohorts (MESA, WGHS, LURIC, and SHIP) are listed where one or more variants may
have been missing. Closest Gene = gene annotation based on location within a gene or the
closest gene for intergenic variants; Locus = genomic location; Published Direction of
Association = direction of association for the variant in the given study; Study = published
study variant was taken from. Table E. Association of allele score with CHD risk factors.
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Fixed effects meta-analysis for association between fibrinogen and CHD risk factors. Fixed
effects meta-analysis was used for all associations despite some evidence for heterogeneity
for HDL P(Q)< 0.05. The association was still not significant in the random effects meta-anal-
ysis. Hypertension and Type II Diabetes were binary variables. Smoking was a categorical out-
come for current, former, or never smokers. Beta = meta-analysis effect estimate; SE = meta-
analysis standard error; P = meta-analysis P; Q = Cochran’s Q; P(Q) = P-value associated with
Cochran’s Q.
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